<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Biol</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosbiol</journal-id>
<journal-title-group>
<journal-title>PLOS Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1544-9173</issn>
<issn pub-type="epub">1545-7885</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pbio.2001307</article-id>
<article-id pub-id-type="publisher-id">pbio.2001307</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Perspective</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Research design</subject><subj-group><subject>Experimental design</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Research design</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Probability theory</subject><subj-group><subject>Probability distribution</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Bayesian statistics</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Bayesian statistics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Bayesian method</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Clinical medicine</subject><subj-group><subject>Clinical trials</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug research and development</subject><subj-group><subject>Clinical trials</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Clinical trials</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Research assessment</subject><subj-group><subject>Reproducibility</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Increasing efficiency of preclinical research by group sequential designs</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Neumann</surname>
<given-names>Konrad</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Grittner</surname>
<given-names>Ulrike</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Piper</surname>
<given-names>Sophie K.</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Rex</surname>
<given-names>Andre</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Florez-Vargas</surname>
<given-names>Oscar</given-names>
</name>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Karystianis</surname>
<given-names>George</given-names>
</name>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Schneider</surname>
<given-names>Alice</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wellwood</surname>
<given-names>Ian</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Siegerink</surname>
<given-names>Bob</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ioannidis</surname>
<given-names>John P. A.</given-names>
</name>
<xref ref-type="aff" rid="aff009"><sup>9</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Kimmelman</surname>
<given-names>Jonathan</given-names>
</name>
<xref ref-type="aff" rid="aff010"><sup>10</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Dirnagl</surname>
<given-names>Ulrich</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
<xref ref-type="aff" rid="aff011"><sup>11</sup></xref>
<xref ref-type="aff" rid="aff012"><sup>12</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Biostatistics and Clinical Epidemiology, Charité Universitätsmedizin Berlin, Berlin, Germany</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Center for Stroke Research, Charité Universitätsmedizin Berlin, Berlin, Germany</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Department of Experimental Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Bio-health Informatics Group, School of Computer Science, The University of Manchester, Manchester, United Kingdom</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Centre for Health Informatics, Macquarie University, Sydney, Australia</addr-line></aff>
<aff id="aff007"><label>7</label> <addr-line>Department of Public Health and Primary Care, Cambridge Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom</addr-line></aff>
<aff id="aff008"><label>8</label> <addr-line>Center for Transforming Biomedical Research, Berlin Institute of Health, Berlin, Germany</addr-line></aff>
<aff id="aff009"><label>9</label> <addr-line>Meta-Research Innovation Center at Stanford (METRICS), and Departments of Medicine, of Health Research and Policy, and of Statistics, Stanford University, Stanford, California, United States of America</addr-line></aff>
<aff id="aff010"><label>10</label> <addr-line>STREAM Research Group, Biomedical Ethics Unit, McGill University, Montreal, Canada</addr-line></aff>
<aff id="aff011"><label>11</label> <addr-line>German Center for Neurodegenerative Diseases (DZNE), Berlin Site, Berlin, Germany</addr-line></aff>
<aff id="aff012"><label>12</label> <addr-line>German Center for Cardiovascular Research (DZHK), Berlin site, Berlin, Germany</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">ulrike.grittner@charite.de</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>3</month>
<year>2017</year>
</pub-date>
<volume>15</volume>
<issue>3</issue>
<elocation-id>e2001307</elocation-id>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>Neumann et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pbio.2001307"/>
<abstract>
<p>Despite the potential benefits of sequential designs, studies evaluating treatments or experimental manipulations in preclinical experimental biomedicine almost exclusively use classical block designs. Our aim with this article is to bring the existing methodology of group sequential designs to the attention of researchers in the preclinical field and to clearly illustrate its potential utility. Group sequential designs can offer higher efficiency than traditional methods and are increasingly used in clinical trials. Using simulation of data, we demonstrate that group sequential designs have the potential to improve the efficiency of experimental studies, even when sample sizes are very small, as is currently prevalent in preclinical experimental biomedicine. When simulating data with a large effect size of d = 1 and a sample size of <italic>n</italic> = 18 per group, sequential frequentist analysis consumes in the long run only around 80% of the planned number of experimental units. In larger trials (<italic>n</italic> = 36 per group), additional stopping rules for futility lead to the saving of resources of up to 30% compared to block designs. We argue that these savings should be invested to increase sample sizes and hence power, since the currently underpowered experiments in preclinical biomedicine are a major threat to the value and predictiveness in this research domain.</p>
</abstract>
<funding-group>
<funding-statement>German Federal Ministry of Education and Research (BMBF) <ext-link ext-link-type="uri" xlink:href="http://www.bmbf.de" xlink:type="simple">www.bmbf.de</ext-link> (grant number 01EO1301). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="1"/>
<page-count count="9"/>
</counts>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Background</title>
<p>Group sizes in preclinical research are seldom informed by statistical power considerations but rather are chosen on practicability [<xref ref-type="bibr" rid="pbio.2001307.ref001">1</xref>, <xref ref-type="bibr" rid="pbio.2001307.ref002">2</xref>]. Typical sample sizes are small, around <italic>n</italic> = 8 per group (<ext-link ext-link-type="uri" xlink:href="http://www.dcn.ed.ac.uk/camarades/" xlink:type="simple">http://www.dcn.ed.ac.uk/camarades/</ext-link>), and are only sufficient to detect relatively large sizes of effects. Consequently, true positives are often missed (false negatives), and many statistically significant findings are due to chance (false positives). Such results lack reproducibility, and the effect sizes are often substantially overestimated (“Winner’s curse”) [<xref ref-type="bibr" rid="pbio.2001307.ref002">2</xref>–<xref ref-type="bibr" rid="pbio.2001307.ref005">5</xref>]. Therefore, various research bodies (e.g., National Institutes of Health, United Kingdom Academy of Medical Sciences) have called for increased sample sizes [<xref ref-type="bibr" rid="pbio.2001307.ref005">5</xref>, <xref ref-type="bibr" rid="pbio.2001307.ref006">6</xref>], as well as other design improvements in preclinical research. Yet, such calls also potentially antagonize the goal of minimizing burdens on animals. Here, we propose the use of sequential study designs to reduce the number of experimental animals required, as well as to increase the efficiency of current preclinical biomedical research. Moreover, our aim with this article is to bring the existing methodology of group sequential designs to the attention of researchers in the preclinical field and to clearly illustrate its potential utility.</p>
</sec>
<sec id="sec002">
<title>Sequential study designs</title>
<p>Conventional study designs in experimental preclinical biomedicine use nonsequential approaches, in which group sizes are predetermined and fixed, and the decision to either accept the (alternative) hypothesis or fail to reject the null hypothesis is made after spending all experimental units in each group. In contrast, a group sequential design is a type of adaptive design that allows for early stopping of an experiment because of efficacy or futility, based on interim analyses before all experimental units are spent [<xref ref-type="bibr" rid="pbio.2001307.ref007">7</xref>–<xref ref-type="bibr" rid="pbio.2001307.ref009">9</xref>], thereby offering an increase in efficiency.</p>
<p>However, interim analyses come at a statistical cost, and special analysis methods and careful preplanning are required. Traditional frequentist statistics can be used to split the overall probability of type I error (α–error) to account for multiple testing [<xref ref-type="bibr" rid="pbio.2001307.ref010">10</xref>, <xref ref-type="bibr" rid="pbio.2001307.ref011">11</xref>], but Bayesian methods are particularly suited, as they can incorporate information from earlier stages of the study. Moreover, Bayesian analysis enables the researcher to use prestudy information as a basis for the prior information about the measure of interest [<xref ref-type="bibr" rid="pbio.2001307.ref008">8</xref>, <xref ref-type="bibr" rid="pbio.2001307.ref009">9</xref>]. As the prior is potentially subjective and the gained posteriors highly dependent not only on the data but also on the chosen prior, the practice of informed priors is hotly contested. Noninformative priors are an option to circumvent this concern [<xref ref-type="bibr" rid="pbio.2001307.ref012">12</xref>, <xref ref-type="bibr" rid="pbio.2001307.ref013">13</xref>].</p>
<p>Group sequential designs are increasingly used in clinical research [<xref ref-type="bibr" rid="pbio.2001307.ref008">8</xref>, <xref ref-type="bibr" rid="pbio.2001307.ref014">14</xref>]. So far, however, they are virtually nonexistent in preclinical experiments. We performed text-mining of the complete PubMed Central Open Access subset (time frame: 2010–2014) and found only one article explicitly describing an original study evaluating a treatment in rats or mice using a sequential design [<xref ref-type="bibr" rid="pbio.2001307.ref015">15</xref>] (<xref ref-type="supplementary-material" rid="pbio.2001307.s003">S1 Text</xref>).</p>
<p>To explore the potential for group sequential designs to increase the efficiency of preclinical studies, we simulated data for two-group comparisons of different effect sizes and compared “costs,” measured by the number of animals required for different group sequential designs, compared to a traditional nonsequential design (<xref ref-type="supplementary-material" rid="pbio.2001307.s003">S1 Text</xref>).</p>
</sec>
<sec id="sec003">
<title>Increase in efficiency</title>
<p>We simulated a mouse experiment in which 36 animals are allocated to two groups. Currently, in most domains of preclinical medicine, group sizes of ten or less are prevalent, leading to grossly underpowered studies [<xref ref-type="bibr" rid="pbio.2001307.ref004">4</xref>]. A group size of 18 animals per group allows the detection of a standardized effect size of d = 1, given traditional constraints of alpha = 0.05 and beta = 0.20. A block design typically used in this type of study needs to include all animals before data analysis. In a group sequential design, an interim analysis is conducted, and a predefined set of rules determine whether the experiment should be continued or not (<xref ref-type="fig" rid="pbio.2001307.g001">Fig 1</xref>).</p>
<fig id="pbio.2001307.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pbio.2001307.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Study design and sequential analysis approach allowing two interim analyses.</title>
<p>Stage 1: 33% of samples acquired, stage 2: 66% of samples acquired, and stage 3: 100% of samples acquired. H<sub>0</sub>: null hypothesis, P: <italic>p</italic>-value, Credible interval: specific Bayesian interval of certainty about an estimate, d: effect size Cohen’s d, α<sub>i</sub>: significance levels for each stage derived from [<xref ref-type="bibr" rid="pbio.2001307.ref011">11</xref>] α<sub>1</sub> = 0.0006, α<sub>2</sub> = 0.0151, α <sub>3</sub> = 0.0471. Additionally, we used a Bayes factor approach (<xref ref-type="table" rid="pbio.2001307.t001">Table 1</xref>) and Pocock boundaries for the frequentist approach (<xref ref-type="supplementary-material" rid="pbio.2001307.s002">S1 Table</xref>). All sequential approaches used were calibrated by using simulations to get a type I error of about 5%.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.2001307.g001" xlink:type="simple"/>
</fig>
<p>Here, we demonstrate only some of many possible analysis approaches (frequentist sequential with O’Brien–Fleming boundaries [<xref ref-type="bibr" rid="pbio.2001307.ref011">11</xref>], with Pocock boundaries [<xref ref-type="bibr" rid="pbio.2001307.ref016">16</xref>] [<xref ref-type="supplementary-material" rid="pbio.2001307.s002">S1 Table</xref>], Bayes Factor, and Bayes credible intervals, <xref ref-type="table" rid="pbio.2001307.t001">Table 1</xref>). See <xref ref-type="boxed-text" rid="pbio.2001307.box001">Box 1</xref> for other approaches and references.</p>
<table-wrap id="pbio.2001307.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pbio.2001307.t001</object-id>
<label>Table 1</label> <caption><title>Early stopping for significance or futility using nonsequential group sequential designs (examples with <italic>n</italic> = 36 or <italic>n</italic> = 72).</title></caption>
<alternatives>
<graphic id="pbio.2001307.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.2001307.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify"/>
<th align="center" colspan="5">Small study (<italic>n</italic> = 36) stop for significance, three stages</th>
<th align="center" colspan="5">Larger study (<italic>n</italic> = 72) stop for significance or futility, two stages</th>
</tr>
<tr>
<th align="justify"/>
<th align="center">Sample size (per group)</th>
<th align="center">Freq. nonseq.</th>
<th align="center">Freq. seq.</th>
<th align="center">Bayes Factor</th>
<th align="center">Bayes (CRI) with noninf. Prior</th>
<th align="center">Sample size (per group)</th>
<th align="center">Freq. nonseq.</th>
<th align="center">Freq. seq.</th>
<th align="center">Bayes Factor</th>
<th align="center">Bayes (CRI) with noninf. Prior</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="11" style="background-color:#BFBFBF"><bold>d = 0</bold></td>
</tr>
<tr>
<td align="justify"><bold>Stage 1</bold> [%] sign./futility<break/><bold>Stage 1 and 2</bold> [%] sign.<break/><bold>Stage 1 and 2 (and 3) = type 1 error</bold> [%] sign.</td>
<td align="center">12 (6 versus 6)<break/>24 (12 versus 12)<break/>36 (18 versus 18)</td>
<td align="center">-<break/>-<break/><bold>5.0</bold></td>
<td align="center">0.1<break/>1.4<break/><bold>4.9</bold></td>
<td align="center">2.3<break/>4.0<break/><bold>5.0</bold></td>
<td align="center">0.4<break/>3.2<break/><bold>5.0</bold></td>
<td align="center">36 (18 versus 18)<break/>-<break/>72 (36 versus 36)</td>
<td align="center">-<break/><break/><bold>5.0</bold></td>
<td align="center">0.8/50.7<break/><break/><bold>5.3</bold></td>
<td align="center">3.5/70.7<break/><break/><bold>5.0</bold></td>
<td align="center">1.1/50.1<break/><break/><bold>5.1</bold></td>
</tr>
<tr>
<td align="justify"><bold>Cost</bold> [mean number of animals]<break/><bold>d</bold><sub><bold>est</bold></sub></td>
<td align="center"><break/></td>
<td align="center">36<break/>0.78</td>
<td align="center">36<break/>0.84</td>
<td align="center">36<break/>1.38</td>
<td align="center">36<break/>1.00</td>
<td align="center"><break/></td>
<td align="center">72<break/>0.54</td>
<td align="center">53<break/>0.55</td>
<td align="center">45<break/>0.77</td>
<td align="center">54<break/>0.57</td>
</tr>
<tr>
<td align="center" colspan="11" style="background-color:#BFBFBF"><bold>d = 0.5</bold></td>
</tr>
<tr>
<td align="justify"><bold>Stage 1</bold> [%] sign./futility<break/><bold>Stage 1 and 2</bold> [%] sign.<break/><bold>Stage 1 and 2 (and 3) = Power</bold> [%] sign.</td>
<td align="center">12 (6 versus 6)<break/>24 (12 versus 12)<break/>36 (18 versus 18)</td>
<td align="center">-<break/>-<break/><bold>30.8</bold></td>
<td align="center">0.4<break/>10.3<break/><bold>31.2</bold></td>
<td align="center">6.4<break/>15.3<break/><bold>24.3</bold></td>
<td align="center">1.0<break/>18.4<break/><bold>30.3</bold></td>
<td align="center">36 (18 versus 18)<break/>-<break/>72 (36 versus 36)</td>
<td align="center"><break/><break/><bold>55.3</bold></td>
<td align="center">9.7/18.8<break/><break/><bold>53.8</bold></td>
<td align="center">25.6/32.5<break/><break/><bold>46.0</bold></td>
<td align="center">11.2/18.5<break/><break/><bold>54.3</bold></td>
</tr>
<tr>
<td align="justify"><bold>Cost</bold> [mean number of animals]<break/><bold>d</bold><sub><bold>est</bold></sub></td>
<td align="center"><break/></td>
<td align="center">36<break/>0.86</td>
<td align="center">35<break/>0.93</td>
<td align="center">34<break/>1.13</td>
<td align="center">34<break/>1.00</td>
<td align="center"><break/></td>
<td align="center">72<break/>0.65</td>
<td align="center">62<break/>0.67</td>
<td align="center">51<break/>0.78</td>
<td align="center">61<break/>0.68</td>
</tr>
<tr>
<td align="center" colspan="11" style="background-color:#BFBFBF"><bold>d = 1.0</bold></td>
</tr>
<tr>
<td align="justify"><bold>Stage 1</bold> [%] sign./futility<break/><bold>Stage 1 and 2</bold> [%] sign.<break/><bold>Stage 1 and 2 (and 3) = Power</bold> [%] sign.</td>
<td align="center">12 (6 versus 6)<break/>24 (12 versus 12)<break/>36 (18 versus 18)</td>
<td align="center">-<break/>-<break/><bold>83.0</bold></td>
<td align="center">1.6<break/>43.6<break/><bold>82.2</bold></td>
<td align="center">22.8<break/>53.3<break/><bold>74.7</bold></td>
<td align="center">4.5<break/>58.4<break/><bold>80.5</bold></td>
<td align="center">36 (18 versus 18)<break/>-<break/>72 (36 versus 36)</td>
<td align="center"><break/><break/><bold>98.7</bold></td>
<td align="center">54.4/0.9<break/><break/><bold>98.1</bold></td>
<td align="center">78.3/2.8<break/><break/><bold>96.1</bold></td>
<td align="center">57.7/0.8<break/><break/><bold>98.2</bold></td>
</tr>
<tr>
<td align="justify"><bold>Cost</bold> [mean number of animals]<break/><bold>d</bold><sub><bold>est</bold></sub></td>
<td align="center"><break/></td>
<td align="center">36<break/>1.09</td>
<td align="center">31<break/>1.16</td>
<td align="center">27<break/>1.27</td>
<td align="center">28<break/>1.14</td>
<td align="center"><break/></td>
<td align="center">72<break/>1.01</td>
<td align="center">52<break/>1.07</td>
<td align="center">43<break/>1.05</td>
<td align="center">51<break/>1.06</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p><bold>Simulations based on a total number of 18 or 36 samples per group. Power or type I error for three different standardized effect sizes Cohen’s d = 0, or 0.5, or 1.0, respectively.</bold> Numbers give <bold>cumulative</bold> percentages of statistically significant trials in percent [%] out of 10,000 simulation runs, as well as “Costs” defined as the long term mean of experimental units, and median estimated effect sizes in significant trials (d<sub>est</sub>). <bold>Small study with <italic>n</italic> = 18 per group:</bold> Stage 1: <italic>n</italic> = 12 (6 versus 6), stage 1 and 2: <italic>n</italic> = 24 (12 versus 12), stage 1 and 2 and 3: <italic>n</italic> = 36 (18 versus 18) experimental units. Stopping rules that allowed early stopping: Freq. nonseq.: α = 0.05; Freq. seq.: significance levels for interim analyses: α<sub>1</sub> = 0.0006, α<sub>2</sub> = 0.0151, α<sub>3</sub> = 0.0471 according to [<xref ref-type="bibr" rid="pbio.2001307.ref011">11</xref>]; Bayes Factor: 3 for each stage; Bayes noninf. prior: CRI for effect size: stage 1: 99.8% CRI, stage 2 and 3: 96.8% CRI.</p></fn>
<fn id="t001fn002"><p><bold>Larger study with <italic>n</italic> = 36 per group:</bold> Stage 1: <italic>n</italic> = 36 (18 versus 18), stage 1 and 2: <italic>n</italic> = 72 (36 versus 36) experimental units. Stopping rules that allowed early stopping for futility or significance: Freq. nonseq.: α = 0.05; Freq seq. [<xref ref-type="bibr" rid="pbio.2001307.ref011">11</xref>]: α<sub>futility</sub> = 0.5, α<sub>1</sub> = 0.0065, α<sub>2</sub> = 0.0525; Bayes Factor: 2 and for futility: 0.5; CRI for effect size d using a Bayesian approach with noninf. prior: stage 1 99% CRI, for futility: zero is included in 50% CRI for effect size d, stage 2 95% CRI.</p></fn>
<fn id="t001fn003"><p>All sequential approaches used were calibrated to get a type I error of about 5%.</p></fn>
<fn id="t001fn004"><p><bold>Abbreviations:</bold> CRI, credible interval; Freq. nonseq., Frequentist nonsequential; Freq. seq., Frequentist sequential; Noninf., Noninformative.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The O’Brien–Fleming boundaries in the frequentist sequential approach keep the alpha level for the final analysis (stage 3) approximately as high as for the classical block design. Additionally, the same scenarios using Pocock boundaries can be found in <xref ref-type="supplementary-material" rid="pbio.2001307.s002">S1 Table</xref>. It should be noted that the frequentist approaches refer to null hypothesis significance testing, whereas the Bayes Factor approach is basically a model comparison, and the other Bayesian approach uses credible intervals for estimates. These are different methods that might answer different research questions, as outlined by Morey et al. [<xref ref-type="bibr" rid="pbio.2001307.ref027">27</xref>]. However, here, we used all methods for deriving stopping criteria and decisions about efficacy or futility.</p>
<p>Our simulations showed that in an experimental setting typical for current experimental biomedicine, if the effect exists, group sequential designs have lower costs because of early stopping for futility or efficacy (<xref ref-type="table" rid="pbio.2001307.t001">Table 1</xref>). With a large true effect size (d = 1) and <italic>n</italic> = 18 per group, sequential analyses that stop for significance reduce the costs up to 20%, while the power of these analyses do not differ from the traditional block design. Underpowered studies (d = 0.5 scenarios, <xref ref-type="table" rid="pbio.2001307.t001">Table 1</xref>) show only approximately 30% power for classical as well as sequential approaches, while the reduction in costs through sequential design is minor. This stresses the need for sufficiently powered studies even with sequential analyses. As expected, average effect sizes among successful experiments are overestimated in the traditional approach and slightly more so in the sequential design. Larger experiments that can stop for both success and futility show a similar pattern: sequential analysis has similar power as the traditional approach, while costs are reduced substantially.</p>
</sec>
<sec id="sec004">
<title>Efficiency versus predictive ability in a real-world setting</title>
<p>The simulations above differ from the real-world setting where we, despite setting out to detect an effect beyond a certain (biological) threshold, never know the true effect size a priori. In another set of simulations, we therefore assumed a specific distribution of true effect sizes within the universe of studies that can be performed. Such distributions may vary in different fields of research. This is relevant because, as with different effect size distributions and the chance of early stopping an experiment, the predictive probability of a “statistically significant” signal, i.e., the probability that a significant result really reflects a true effect, is different. To understand the ability to predict in a real-world setting, we simulated analyses with two different distributions of effect estimates: one optimistic and one pessimistic (<xref ref-type="fig" rid="pbio.2001307.g002">Fig 2</xref>, <xref ref-type="supplementary-material" rid="pbio.2001307.s001">S1 Fig</xref>). Through these simulations, we estimated the probabilities of obtaining an effect of any size d &gt; 0 or at least size d ≥ 0.5 for both the traditional frequentist approach and group sequential designs. Overall, there are no major differences in these probabilities between the traditional and sequential approaches—despite the fact that the latter uses fewer animals. More importantly, this table shows that the main driver behind these probabilities is the a priori distribution of effect sizes (optimistic versus pessimistic).</p>
<fig id="pbio.2001307.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pbio.2001307.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Predictive capabilities of sequential designs compared to traditional nonsequential design for two different scenarios of potential effect size distributions.</title>
<p>Upper left: “optimistic” scenario with more large effect sizes. Upper right: “pessimistic” scenario with mostly effect sizes of 0. Bottom: Probability of getting a significant test result reflecting a true effect of d ≠ 0 or d ≥ 0.5, respectively, for the two different scenarios of effect size distributions. First, the probabilities P(significant) for getting any significant study results are given, then the corresponding positive predictive values, and, finally, the product of both giving the corresponding overall probability of getting a significant study result that truly represents an effect of d ≠ 0 or d ≥ 0.5 (P<sub>detect true effect</sub>). Stopping rules that allowed early stopping for futility or success as given in <xref ref-type="table" rid="pbio.2001307.t001">Table 1</xref>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pbio.2001307.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec005">
<title>Applications of sequential designs</title>
<p>To the best of our knowledge, there are no groups or programs currently implementing sequential designs in preclinical experimental studies evaluating the efficacy of treatments or interventions. However, we are aware that the practice of interim analyses is applied informally when a statistically significant effect is desired but not found, and the analyses are rerun until significance has been achieved (a practice known as “p-hacking”[<xref ref-type="bibr" rid="pbio.2001307.ref028">28</xref>]). Clearly, this practice inflates false-positive rates, as it violates the preset type I error (α–error) probability by not accounting for multiple testing in these unplanned interim analyses [<xref ref-type="bibr" rid="pbio.2001307.ref010">10</xref>].</p>
<p>Despite the benefits suggested by our simulations, sequential approaches have properties that may limit their application in preclinical experimental biomedicine. The clearest disadvantage of group sequential designs is that each next stage can only be started after the outcome of the preceding stage is fully assessed and analyzed. Sequential analysis may require additional resources to set up, regulate, and monitor the independence of interim analyses, as well as additional statistical expertise. Another consideration is that a step-by-step design might increase the impact of batch and learning effects. However, the largest obstacle might be lack of familiarity with these methods in the field and amongst animal ethics committees, editorial boards, and peers. With this paper, we aim to spur the discussion and stimulate others to consider using sequential designs to increase the efficiency of their studies. Moreover, if in vivo researchers are to get ethical approval for this approach from their various committees, this article might help persuade those committees.</p>
<p>We posit that a substantial number of experiments in preclinical biomedicine can be planned and executed with batch sizes and sufficiently short intervals between treatments and outcome assessments to render them amenable to group sequential design–based methods (for an example, see <xref ref-type="supplementary-material" rid="pbio.2001307.s004">S2 Text</xref>). Sequential designs can lead to a substantial reduction in animal resource. When these savings are invested in increased sample sizes (which, paradoxically, may not be higher than the current ones), sequential designs have the potential to increase the predictive ability of preclinical biomedical experiments and to reduce the current unacceptable levels of waste due to underpowered studies.</p>
<boxed-text id="pbio.2001307.box001" position="float">
<sec id="sec006">
<title>Box 1. Points to consider when planning a group sequential design study</title>
<p>Planning a study design as a group sequential design requires considerations before starting the study (see [<xref ref-type="bibr" rid="pbio.2001307.ref017">17</xref>]; [<xref ref-type="bibr" rid="pbio.2001307.ref018">18</xref>]):</p>
</sec>
<sec id="sec007">
<title>Type of adaptive design</title>
<list list-type="bullet">
<list-item><p>Group sequential design is one simple type of adaptive design, in which the sample size is adapted during the study.</p></list-item>
<list-item><p>Other types of adaptive design, such as designs with sample size reestimation, adaptive dose-response designs, treatment selection designs, or adaptive randomization designs, should be considered as well.</p></list-item>
</list>
</sec>
<sec id="sec008">
<title>Feasibility</title>
<p>Is it feasible for the planned study:</p>
<list list-type="bullet">
<list-item><p>to plan larger sample sizes than for fixed designs with the same power (even if the expected sample size in case of an effect might be lower than for fixed designs)?</p></list-item>
<list-item><p>to include additional time for the interim analysis? How many interim steps, and at which points, are feasible?</p></list-item>
</list>
</sec>
<sec id="sec009">
<title>Preplanning</title>
<p>This includes:</p>
<list list-type="bullet">
<list-item><p>clearly specified hypotheses (adaptation should not be done with regard to generating hypotheses in confirmatory studies),</p></list-item>
<list-item><p>decisions about reasons for early stopping: because of efficacy, futility, or both (stopping for futility is more important for larger studies),</p></list-item>
<list-item><p>decisions about stopping criteria to reject the null hypothesis/or stop because of futility at each stage (related to power, type I error, frequentist or Bayesian kind of analysis, number of stages, sample size at each stage), and</p></list-item>
<list-item><p>sample size estimation (depending on kind of statistical test, power, type I error, assumed effect size, number of stages, stopping criteria).</p></list-item>
</list>
</sec>
<sec id="sec010">
<title>Type I error (frequentist approach) [<xref ref-type="bibr" rid="pbio.2001307.ref019">19</xref>]</title>
<list list-type="bullet">
<list-item><p>Because of multiple testing, type I error is inflated, but different methods of alpha-adjustment ensure an overall type I error rate of 0.05:</p></list-item>
<list-item><p>Pocock [<xref ref-type="bibr" rid="pbio.2001307.ref016">16</xref>]: same significance level at each stage (e.g., three stages (two interim analyses): α = 0.0221 at each stage) (disadvantage: low level at the final stage, which makes it more difficult to get a significant result).</p></list-item>
<list-item><p>O’Brien–Fleming [<xref ref-type="bibr" rid="pbio.2001307.ref011">11</xref>]: significance level is very conservative at early stages and almost 0.05 at the final stage (e.g., three stages: α<sub>1</sub> = 0.0006, α<sub>2</sub> = 0.0151, α<sub>3</sub> = 0.0471) (advantage: almost 0.05 at the final stage).</p></list-item>
<list-item><p>Haybittle–Peto [<xref ref-type="bibr" rid="pbio.2001307.ref020">20</xref>,<xref ref-type="bibr" rid="pbio.2001307.ref021">21</xref>]: at all interim stages α<sub>i</sub> = 0.001, at the final stage: α<sub>final</sub> = 0.05 (advantage: easy to implement and understand and 0.05 level at the final stage, disadvantage: hard to stop early).</p></list-item>
<list-item><p>Other more flexible approaches with regard to sample size at stages are also possible (using alpha-spending functions [<xref ref-type="bibr" rid="pbio.2001307.ref022">22</xref>]).</p></list-item>
</list>
</sec>
<sec id="sec011">
<title>Bayesian approaches [<xref ref-type="bibr" rid="pbio.2001307.ref023">23</xref>]</title>
<list list-type="bullet">
<list-item><p>Points of consideration with regard to type of design, feasibility, and preplanning are similar to designs with frequentist approaches.</p></list-item>
<list-item><p>Type I error normally is not of importance in Bayesian frameworks.</p></list-item>
<list-item><p>But, regulatory authorities (e.g., [<xref ref-type="bibr" rid="pbio.2001307.ref024">24</xref>]) expect evaluation of type I error also for Bayesian statistics.</p></list-item>
</list>
<p><bold>Software</bold> for deriving and describing group sequential designs (including power considerations and sample size estimation):</p>
<list list-type="bullet">
<list-item><p>R package <monospace>gsDesign</monospace> (frequentist approach, [<xref ref-type="bibr" rid="pbio.2001307.ref025">25</xref>])</p></list-item>
<list-item><p>R package <monospace>gsbDesign</monospace> (Bayesian approach, [<xref ref-type="bibr" rid="pbio.2001307.ref026">26</xref>])</p></list-item>
</list>
</sec>
</boxed-text>
</sec>
<sec id="sec012">
<title>Supporting information</title>
<supplementary-material id="pbio.2001307.s001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pbio.2001307.s001" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Predictive capabilities of sequential design (Pocock boundaries).</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pbio.2001307.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pbio.2001307.s002" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Early stopping for significance or futility using sequential group sequential design with Pocock-boundaries.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pbio.2001307.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pbio.2001307.s003" xlink:type="simple">
<label>S1 Text</label>
<caption>
<title>Supporting materials and methods.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pbio.2001307.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pbio.2001307.s004" xlink:type="simple">
<label>S2 Text</label>
<caption>
<title>Illustrative example comparing conventional and group sequential designs using real experimental data from a pre-clinical study in mice.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn001">
<p><bold>Provenance:</bold> Not commissioned; externally peer reviewed.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="pbio.2001307.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kilkenny</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Parsons</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Kadyszewski</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Festing</surname> <given-names>MF</given-names></name>, <name name-style="western"><surname>Cuthill</surname> <given-names>IC</given-names></name>, <name name-style="western"><surname>Fry</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Survey of the quality of experimental design, statistical analysis and reporting of research using animals</article-title>. <source>PLoS ONE</source>. <year>2009</year>;<volume>4</volume>(<issue>11</issue>):<fpage>e7824</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0007824" xlink:type="simple">10.1371/journal.pone.0007824</ext-link></comment> <object-id pub-id-type="pmid">19956596</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aban</surname> <given-names>IB</given-names></name>, <name name-style="western"><surname>George</surname> <given-names>B</given-names></name>. <article-title>Statistical considerations for preclinical studies</article-title>. <source>Experimental neurology</source>. <year>2015</year>;<volume>270</volume>:<fpage>82</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.expneurol.2015.02.024" xlink:type="simple">10.1016/j.expneurol.2015.02.024</ext-link></comment> <object-id pub-id-type="pmid">25725352</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begley</surname> <given-names>CG</given-names></name>, <name name-style="western"><surname>Ioannidis</surname> <given-names>JP</given-names></name>. <article-title>Reproducibility in science improving the standard for basic and preclinical research</article-title>. <source>Circulation research</source>. <year>2015</year>;<volume>116</volume>(<issue>1</issue>):<fpage>116</fpage>–<lpage>26</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCRESAHA.114.303819" xlink:type="simple">10.1161/CIRCRESAHA.114.303819</ext-link></comment> <object-id pub-id-type="pmid">25552691</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Button</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Ioannidis</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Mokrysz</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Nosek</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Flint</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Robinson</surname> <given-names>ES</given-names></name>, <etal>et al</etal>. <article-title>Power failure: why small sample size undermines the reliability of neuroscience</article-title>. <source>Nature Reviews Neuroscience</source>. <year>2013</year>;<volume>14</volume>(<issue>5</issue>):<fpage>365</fpage>–<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrn3475" xlink:type="simple">10.1038/nrn3475</ext-link></comment> <object-id pub-id-type="pmid">23571845</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Glasziou</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Chalmers</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Nasser</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bossuyt</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Korevaar</surname> <given-names>DA</given-names></name>, <etal>et al</etal>. <article-title>Increasing value and reducing waste in biomedical research: who's listening?</article-title> <source>The Lancet</source>. <year>2015</year>.</mixed-citation></ref>
<ref id="pbio.2001307.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cressey</surname> <given-names>D</given-names></name>. <article-title>UK funders demand strong statistics for animal studies</article-title>. <source>Nature</source>. <year>2015</year>;<volume>520</volume>(<issue>7547</issue>):<fpage>271</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/520271a" xlink:type="simple">10.1038/520271a</ext-link></comment> <object-id pub-id-type="pmid">25877180</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Majid</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bae</surname> <given-names>O-N</given-names></name>, <name name-style="western"><surname>Redgrave</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Teare</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Ali</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Zemke</surname> <given-names>D</given-names></name>. <article-title>The Potential of Adaptive Design in Animal Studies</article-title>. <source>International Journal of Molecular Sciences</source>. <year>2015</year>;<volume>16</volume>(<issue>10</issue>):<fpage>24048</fpage>–<lpage>58</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/ijms161024048" xlink:type="simple">10.3390/ijms161024048</ext-link></comment> <object-id pub-id-type="pmid">26473839</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lakens</surname> <given-names>D</given-names></name>. <article-title>Performing high-powered studies efficiently with sequential analyses</article-title>. <source>European Journal of Social Psychology</source>. <year>2014</year>;<volume>44</volume>(<issue>7</issue>):<fpage>701</fpage>–<lpage>10</lpage>.</mixed-citation></ref>
<ref id="pbio.2001307.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schönbrodt</surname> <given-names>FD</given-names></name>, <name name-style="western"><surname>Wagenmakers</surname> <given-names>E-J</given-names></name>, <name name-style="western"><surname>Zehetleitner</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Perugini</surname> <given-names>M</given-names></name>. <article-title>Sequential Hypothesis Testing With Bayes Factors: Efficiently Testing Mean Differences</article-title>. <year>2015</year>. <source>Psychological Methods</source>.</mixed-citation></ref>
<ref id="pbio.2001307.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sainani</surname> <given-names>KL</given-names></name>. <article-title>The problem of multiple testing</article-title>. <source>PM&amp;R</source>. <year>2009</year>;<volume>1</volume>(<issue>12</issue>):<fpage>1098</fpage>–<lpage>103</lpage>.</mixed-citation></ref>
<ref id="pbio.2001307.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>O'Brien</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Fleming</surname> <given-names>TR</given-names></name>. <article-title>A multiple testing procedure for clinical trials</article-title>. <source>Biometrics</source>. <year>1979</year>:<fpage>549</fpage>–<lpage>56</lpage>. <object-id pub-id-type="pmid">497341</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref012"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lindley DV, editor The use of prior probability distributions in statistical inference and decision. Proc 4th Berkeley Symp on Math Stat and Prob; 1961.</mixed-citation></ref>
<ref id="pbio.2001307.ref013"><label>13</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Spiegelhalter</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Abrams</surname> <given-names>KR</given-names></name>, <name name-style="western"><surname>Myles</surname> <given-names>JP</given-names></name>. <source>Bayesian approaches to clinical trials and health-care evaluation</source>: <publisher-name>John Wiley &amp; Sons</publisher-name>; <year>2004</year>.</mixed-citation></ref>
<ref id="pbio.2001307.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bhatt</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>Mehta</surname> <given-names>C</given-names></name>. <article-title>Adaptive designs for clinical trials</article-title>. <source>New England Journal of Medicine</source>. <year>2016</year>;<volume>375</volume>(<issue>1</issue>):<fpage>65</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMra1510061" xlink:type="simple">10.1056/NEJMra1510061</ext-link></comment> <object-id pub-id-type="pmid">27406349</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Miranda</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Stanley</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Gore</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Turner</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Dias</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Rees</surname> <given-names>H</given-names></name>. <article-title>A preclinical physiological assay to test modulation of knee joint pain in the spinal cord: effects of oxycodone and naproxen</article-title>. <source>PLoS ONE</source>. <year>2014</year>; <volume>9</volume>(<issue>8</issue>):<fpage>e106108</fpage>. Epub 2014/08/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0106108" xlink:type="simple">10.1371/journal.pone.0106108</ext-link></comment> <object-id pub-id-type="pmid">25157947</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pocock</surname> <given-names>SJ</given-names></name>. <article-title>Interim analyses for randomized clinical trials: the group sequential approach</article-title>. <source>Biometrics</source>. <year>1982</year>;<volume>38</volume>(<issue>1</issue>):<fpage>153</fpage>–<lpage>62</lpage>. Epub 1982/03/01. <object-id pub-id-type="pmid">7082757</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref017"><label>17</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>He</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Pinheiro</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kuznetsova</surname> <given-names>OM</given-names></name>. <source>Practical considerations for adaptive trial design and implementation</source>: <publisher-name>Springer</publisher-name>; <year>2014</year>.</mixed-citation></ref>
<ref id="pbio.2001307.ref018"><label>18</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Wassmer</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Brannath</surname> <given-names>W</given-names></name>. <chapter-title>Group sequential and confirmatory adaptive designs in clinical trials</chapter-title>. <source>Springer series in pharmaceutical statistics</source>; <year>2016</year>.</mixed-citation></ref>
<ref id="pbio.2001307.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schulz</surname> <given-names>KF</given-names></name>, <name name-style="western"><surname>Grimes</surname> <given-names>DA</given-names></name>. <article-title>Multiplicity in randomised trials II: subgroup and interim analyses</article-title>. <source>Lancet (London, England)</source>. <year>2005</year>;<volume>365</volume>(<issue>9471</issue>):<fpage>1657</fpage>–<lpage>61</lpage>. Epub 2005/05/12.</mixed-citation></ref>
<ref id="pbio.2001307.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Peto</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Pike</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Armitage</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Breslow</surname> <given-names>NE</given-names></name>, <name name-style="western"><surname>Cox</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Howard</surname> <given-names>SV</given-names></name>, <etal>et al</etal>. <article-title>Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design</article-title>. <source>British journal of cancer</source>. <year>1976</year>;<volume>34</volume>(<issue>6</issue>):<fpage>585</fpage>–<lpage>612</lpage>. Epub 1976/12/01. <object-id pub-id-type="pmid">795448</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Haybittle</surname> <given-names>JL</given-names></name>. <article-title>Repeated assessment of results in clinical trials of cancer treatment</article-title>. <source>The British journal of radiology</source>. <year>1971</year>;<volume>44</volume>(<issue>526</issue>):<fpage>793</fpage>–<lpage>7</lpage>. Epub 1971/10/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1259/0007-1285-44-526-793" xlink:type="simple">10.1259/0007-1285-44-526-793</ext-link></comment> <object-id pub-id-type="pmid">4940475</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DeMets</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>Lan</surname> <given-names>KK</given-names></name>. <article-title>Interim analysis: the alpha spending function approach</article-title>. <source>Statistics in medicine</source>. <year>1994</year>;<volume>13</volume>(<issue>13–14</issue>):<fpage>1341</fpage>–<lpage>52</lpage>; discussion 53–6. Epub 1994/07/15. <object-id pub-id-type="pmid">7973215</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gsponer</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Gerber</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Bornkamp</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Ohlssen</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Vandemeulebroecke</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Schmidli</surname> <given-names>H</given-names></name>. <article-title>A practical guide to Bayesian group sequential designs</article-title>. <source>Pharmaceutical statistics</source>. <year>2014</year>;<volume>13</volume>(<issue>1</issue>):<fpage>71</fpage>–<lpage>80</lpage>. Epub 2013/09/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pst.1593" xlink:type="simple">10.1002/pst.1593</ext-link></comment> <object-id pub-id-type="pmid">24038922</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref024"><label>24</label><mixed-citation publication-type="book" xlink:type="simple"><collab>US Food and Drug Administration</collab>. <source>Guidance for the use of Bayesian statistics in medical device clinical trials</source>. <publisher-loc>Maryland</publisher-loc>: <publisher-name>US Food and Drug Administration</publisher-name>; <year>2010</year>.</mixed-citation></ref>
<ref id="pbio.2001307.ref025"><label>25</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Anderson</surname> <given-names>K</given-names></name>. <chapter-title>gsDesign: Group Sequential Design</chapter-title>. <source>R package</source> <edition>version 3.0–1</edition>. <ext-link ext-link-type="uri" xlink:href="http://CRAN.R-project.org/package=gsDesign" xlink:type="simple">http://CRAN.R-project.org/package=gsDesign</ext-link>; <year>2016</year>.</mixed-citation></ref>
<ref id="pbio.2001307.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gerber</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Gsponer</surname> <given-names>T</given-names></name>. <article-title>gsbDesign: An R Package for Evaluating the Operating Characteristics of a Group Sequential Bayesian Design</article-title>. <source>Journal of Statistical Software</source>, <volume>69</volume>(<issue>11</issue>), <fpage>1</fpage>–<lpage>27</lpage>.</mixed-citation></ref>
<ref id="pbio.2001307.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morey</surname> <given-names>RD</given-names></name>, <name name-style="western"><surname>Rouder</surname> <given-names>JN</given-names></name>, <name name-style="western"><surname>Verhagen</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wagenmakers</surname> <given-names>EJ</given-names></name>. <article-title>Why hypothesis tests are essential for psychological science: a comment on Cumming (2014)</article-title>. <source>Psychological science</source>. <year>2014</year>;<volume>25</volume>(<issue>6</issue>):<fpage>1289</fpage>–<lpage>90</lpage>. Epub 2014/03/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/0956797614525969" xlink:type="simple">10.1177/0956797614525969</ext-link></comment> <object-id pub-id-type="pmid">24604147</object-id></mixed-citation></ref>
<ref id="pbio.2001307.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Head</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Holman</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Lanfear</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kahn</surname> <given-names>AT</given-names></name>, <name name-style="western"><surname>Jennions</surname> <given-names>MD</given-names></name>. <article-title>The extent and consequences of p-hacking in science</article-title>. <source>PLoS Biol</source>. <year>2015</year>;<volume>13</volume>(<issue>3</issue>):<fpage>e1002106</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pbio.1002106" xlink:type="simple">10.1371/journal.pbio.1002106</ext-link></comment> <object-id pub-id-type="pmid">25768323</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>